|Bid||1.6550 x 999400|
|Ask||1.6600 x 1370800|
|Day's range||1.6450 - 1.6950|
|52-week range||1.5525 - 2.3350|
|Beta (5Y monthly)||1.22|
|PE ratio (TTM)||11.86|
|Earnings date||23 Aug 2023|
|Forward dividend & yield||0.14 (8.43%)|
|Ex-dividend date||02 Mar 2023|
|1y target est||1.11|
Key Insights Significant control over Platinum Investment Management by retail investors implies that the general...
Every investor in Platinum Investment Management Limited ( ASX:PTM ) should be aware of the most powerful shareholder...
We think intelligent long term investing is the way to go. But unfortunately, some companies simply don't succeed...
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measuresEuropean Commission decision on marketing authorization application (MAA) expected in approximately 60 days If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG) Breda, the Netherlands—June 24, 2022—argenx (Eur